Abstract
Supplementary Figure 1. Study Design of the BaseTIL trial. The BaseTIL trial was a phase I trial of tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade with nivolumab for patients with metastatic melanoma.